Jove
Visualize
Contáctanos
JoVE
x logofacebook logolinkedin logoyoutube logo
ACERCA DE JoVE
Visión GeneralLiderazgoBlogCentro de Ayuda JoVE
AUTORES
Proceso de PublicaciónConsejo EditorialAlcance y PolíticasRevisión por ParesPreguntas FrecuentesEnviar
BIBLIOTECARIOS
TestimoniosSuscripcionesAccesoRecursosConsejo Asesor de BibliotecasPreguntas Frecuentes
INVESTIGACIÓN
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchivo
EDUCACIÓN
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualCentro de Recursos para ProfesoresSitio de Profesores
Términos y Condiciones de Uso
Política de Privacidad
Políticas

Videos de Conceptos Relacionados

Cell-mediated Immune Responses01:40

Cell-mediated Immune Responses

83.1K
Overview
83.1K
Tumor Immunotherapy01:27

Tumor Immunotherapy

1.7K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.7K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K
Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

6.4K
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
6.4K
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

6.8K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
6.8K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.6K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.6K

También podría leer

Artículos Relacionados

Artículos vinculados a este trabajo por autores compartidos, revista y gráfico de citas.

Ordenar por
Same author

Transcriptional and Epigenetic Plasticity Drive an Alternative Non-clonal Mechanism of Resistance to <i>Kras</i> <sup>G12D</sup> Inhibition in Pancreatic Cancer.

Cancer communications (London, England)·2026
Same author

c-FLIP as a master regulator of immune homeostasis and disease mechanisms.

Cell death & disease·2026
Same author

The sialic shield of leukemia cells.

Science (New York, N.Y.)·2026
Same author

Longitudinal Comparison of Calprotectin and C-Reactive Protein in Rheumatoid Arthritis: Real-World Evidence Across Three Targeted Therapies.

Diagnostics (Basel, Switzerland)·2026
Same author

A comprehensive longitudinal analysis of the cellular immune response specific to the spike protein in healthcare workers vaccinated against SARS-CoV-2- ORCHESTRA Project.

Frontiers in immunology·2025
Same author

Design, Synthesis, and Structural Evolution of Pseudo-Natural Product IDO1 Inhibitors and Degraders.

Angewandte Chemie (International ed. in English)·2025

Video Experimental Relacionado

Updated: Jan 2, 2026

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells
09:04

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

1.3K

Cerca del hueso: Evasión de la inmunoterapia en el punto de control específico del tejido

Vincenzo Bronte1

  • 1Department of Medicine of University of Verona, Policlinico GB Rossi, Piazzale L.A. Scuro 10, 37134 Verona, Italy.

Cell
|November 16, 2019
PubMed
Resumen

La resistencia a la terapia de punto de control inmunológico puede depender de dónde se propague el cáncer. Las metástasis óseas crean un entorno hostil que dificulta la eficacia del tratamiento.

Más Videos Relacionados

Tumor Transplantation for Assessing the Dynamics of Tumor-Infiltrating CD8+ T Cells in Mice
07:36

Tumor Transplantation for Assessing the Dynamics of Tumor-Infiltrating CD8+ T Cells in Mice

Published on: June 12, 2021

7.4K
Generation of Orthotopic Pancreatic Tumors and Ex vivo Characterization of Tumor-Infiltrating T Cell Cytotoxicity
06:16

Generation of Orthotopic Pancreatic Tumors and Ex vivo Characterization of Tumor-Infiltrating T Cell Cytotoxicity

Published on: December 7, 2019

13.3K

Videos de Experimentos Relacionados

Last Updated: Jan 2, 2026

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells
09:04

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

1.3K
Tumor Transplantation for Assessing the Dynamics of Tumor-Infiltrating CD8+ T Cells in Mice
07:36

Tumor Transplantation for Assessing the Dynamics of Tumor-Infiltrating CD8+ T Cells in Mice

Published on: June 12, 2021

7.4K
Generation of Orthotopic Pancreatic Tumors and Ex vivo Characterization of Tumor-Infiltrating T Cell Cytotoxicity
06:16

Generation of Orthotopic Pancreatic Tumors and Ex vivo Characterization of Tumor-Infiltrating T Cell Cytotoxicity

Published on: December 7, 2019

13.3K

Área de la Ciencia:

  • En el campo de la oncología
  • Inmunología
  • Metástasis del cáncer

Sus antecedentes:

  • Los inhibidores del punto de control inmunológico (ICI) han revolucionado el tratamiento del cáncer.
  • La resistencia a los ICI es un desafío clínico significativo.
  • La heterogeneidad del microambiente tumoral influye en la respuesta al tratamiento.

Objetivo del estudio:

  • Investigar el impacto del sitio metastásico en la resistencia a la terapia de punto de control inmunológico.
  • Caracterizar el papel del microambiente óseo en la resistencia al tratamiento.

Principales métodos:

  • Análisis de tumores primarios frente a las metástasis óseas.
  • Evaluación de la infiltración y función de las células inmunes en diferentes sitios metastásicos.
  • Modelos in vivo e in vitro para el estudio del nicho metastásico óseo.

Principales resultados:

  • La ubicación de las metástasis influye significativamente en la resistencia a la ICI.
  • Las metástasis óseas establecen un microambiente particularmente hostil.
  • Factores celulares y moleculares específicos dentro del hueso promueven la resistencia.

Conclusiones:

  • El sitio metastásico es un determinante crítico de la eficacia de la terapia de control inmunológico.
  • Dirigirse al microambiente óseo puede superar la resistencia.
  • Las futuras estrategias deben considerar el nicho metastásico en el diseño del tratamiento.